Cas 28340-72-9,Benzonitrile, 2-amino-4-(4-morpholinyl)-

28340-72-9

Post Buying Request

Basic information

Product Name: Benzonitrile, 2-amino-4-(4-morpholinyl)-
Synonyms:
CAS NO:28340-72-9
Molecular Formula: C11H13N3O
Molecular Weight: 203.244
EINECS: N/A
Product Categories: N/A
Mol File: 28340-72-9.mol

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: Benzonitrile, 2-amino-4-(4-morpholinyl)-(CAS DataBase Reference)
NIST Chemistry Reference: Benzonitrile, 2-amino-4-(4-morpholinyl)-(28340-72-9)
EPA Substance Registry System: Benzonitrile, 2-amino-4-(4-morpholinyl)-(28340-72-9)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 28340-72-9(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

28340-72-9 Suppliers

Recommended suppliers

28340-72-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 28340-72-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,3,4 and 0 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 28340-72:
(7*2)+(6*8)+(5*3)+(4*4)+(3*0)+(2*7)+(1*2)=109
109 % 10 = 9
So 28340-72-9 is a valid CAS Registry Number.

28340-72-9Upstream product

28340-72-9Downstream Products

28340-72-9Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND THEIR USES

-

Page/Page column 26, (2011/01/05)

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

FUSED AZOLE-PYRIMIDINE DERIVATIVES

-

Page 110, (2008/06/13)

The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidy

Cyclic guanidines. 17. Novel (N-substituted amino)imidazo[2,1-b]quinazolin-2-ones: Water-soluble platelet aggregation inhibitors

Ishikawa,Saegusa,Inamura,Sakuma,Ashida

, p. 1387 - 1393 (2007/10/02)

A series of novel 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one derivatives substituted with a secondary amino group has been prepared and tested for the activities of inhibiting platelet aggregation in rats in vitro and ex vivo. Most of the compounds

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 28340-72-9